MARKET

DRRX

DRRX

DURECT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6879
-0.0249
-3.49%
Closed 16:00 01/26 EST
OPEN
0.7200
PREV CLOSE
0.7128
HIGH
0.7338
LOW
0.6625
VOLUME
516.52K
TURNOVER
--
52 WEEK HIGH
2.947
52 WEEK LOW
0.6115
MARKET CAP
156.50M
P/E (TTM)
-4.0041
1D
5D
1M
3M
1Y
5Y
Stocks That Hit 52-Week Lows On Tuesday
  Tuesday morning saw 454 companies set new 52-week lows.
Benzinga · 01/18 15:59
Here's Why Durect (DRRX) is Poised for a Turnaround After Losing 17.1% in 4 Weeks
Durect (DRRX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks · 01/13 15:00
DURECT Corporation to Participate in H.C. Wainwright Bioconnect Conference
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer, and Dr. Norman Sussman, Chief Medical Officer will present at the H.C. Wainwright Bioconnect Conference which will b...
PR Newswire · 01/06 21:05
BRIEF-Durect And Innocoll Announce A $136 Million U.S. Licensing Agreement For Posimir® (Bupivacaine Solution)
reuters.com · 12/22/2021 12:47
DURECT And Innocoll Announce $136M US Licensing Agreement For POSIMIR (Bupivacaine Solution); Innocoll To Make Near-Term Payments To DURECT Of $6M With Potential For $130M In Milestones
DURECT Corporation (NASDAQ:DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, exclusive development
Benzinga · 12/22/2021 12:31
DURECT and Innocoll Announce a $136 Million U.S. Licensing Agreement for POSIMIR® (Bupivacaine Solution)
DURECT Corporation (Nasdaq: DRRX) today announced a licensing agreement granting Innocoll Biotherapeutics plc, a specialty pharmaceutical company and portfolio business of Gurnet Point Capital, exclusive development and commercialization rights to POSIMIR®...
PR Newswire · 12/22/2021 12:30
Do Institutions Own DURECT Corporation (NASDAQ:DRRX) Shares?
If you want to know who really controls DURECT Corporation ( NASDAQ:DRRX ), then you'll have to look at the makeup of...
Simply Wall St. · 12/22/2021 10:45
BRIEF-Durect Corporation Expands Board Of Directors With Appointment Of Biopharmaceutical Industry Finance Veteran Peter Garcia
reuters.com · 12/14/2021 14:24
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of DRRX. Analyze the recent business situations of DURECT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DRRX stock price target is 6.00 with a high estimate of 6.00 and a low estimate of 6.00.
High6.00
Average6.00
Low6.00
Current 0.6879
EPS
Actual
Estimate
-0.04-0.02-0.000.01
Q4 2020
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Institutional Holdings
Institutions: 153
Institutional Holdings: 145.12M
% Owned: 63.79%
Shares Outstanding: 227.51M
TypeInstitutionsShares
Increased
38
2.06M
New
9
367.51K
Decreased
32
3.32M
Sold Out
8
334.28K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.73%
Pharmaceuticals & Medical Research
-0.45%
Key Executives
Non-Executive Chairman/Independent Director
David Hoffmann
President/Chief Executive Officer/Director
James Brown
Chief Financial Officer/IR Contact Officer
Michael Arenberg
Senior Vice President
Judy Joice
Other
Norman Sussman
Director
Gail Farfel
Director
Peter Garcia-Webb
Independent Director
Mohammad Azab
Independent Director
Simon Benito
Independent Director
Terrence Blaschke
Independent Director
Gail Maderis
Independent Director
Judith Robertson
No Data
About DRRX
DURECT Corporation is a biopharmaceutical company focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. Its other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. DUR‑928 is a candidate in its Epigenetic Regulator Program. Injectable DUR-928 is under testing in a Phase II clinical trial and oral DUR-928 is under testing in a Phase I clinical trial. The chronic toxicity of DUR-928 was further assessed in a 6-month oral study in rats and in a 9-month oral study in dogs. POSIMIR enabling continuous sustained delivery of bupivacaine, a non-opioid local analgesic, over 3 days in adults to control post-surgical pain of patients.

Webull offers kinds of DURECT Corporation stock information, including NASDAQ:DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.